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Abstract
Background: The regulation of protein phosphorylation requires a balance in the activity of
protein kinases and protein phosphatases. Our previous data indicates that Src can increase ERK
activity through Raf kinase in response to ischemic stimuli. This study examined the molecular
mechanisms by which Src activates ERK cascade through protein phosphatases following cerebral
ischemia.
Results: Ischemia-induced Src activation is followed by phosphorylation of PP2A at Tyr307 leading
to its inhibition in the rat hippocampus. SU6656, a Src inhibitor, up-regulates PP2A activity,
resulting in a significant decreased activity in ERK and its targets, CREB and ERα. In addition, the
PP2A inhibitor, cantharidin, led to an up-regulation of ERK activity and was able to counteract Src
inhibition during ischemia.
Conclusion: Src induces up-regulation of ERK activity and its target transcription factors, CREB
and ERα, through attenuation of PP2A activity. Therefore, activation of ERK is the result of a
crosstalk between two pathways, Raf-dependent positive regulators and PP2A-dependent negative
regulators.
Background
When blood flow is decreased to the brain, cerebral
ischemia, a complex signaling network is activated. Exci-
totoxicity can be induced by an increase in intraneuronal
Ca2+ through calcium ion channels, such as the N-methyl-
D-aspartic acid (NMDA) receptor, L-type voltage-gated
calcium channels (L-VGCC) and IP3 receptor. An influx in
intraneuronal Ca2+ is a key mediator in multiple intracel-
lular signaling cascades after ischemia [1]. Extracellular
signal – regulated kinase (ERK), a member of the mitogen-
activated protein kinase (MAPK) family, is activated in a
Ca2+-dependent manner in cerebral ischemia [2-4]. ERK is
regulated via phosphorylation at various motifs. Previous
studies have demonstrated that ERK is activated by vari-
ous upstream kinases, such as Akt and Src, by the Raf/
MEK/ERK signaling cascade [5-7]. In response to ischemic
stimuli, active Src kinase activates ERK through Raf phos-
phorylation at Tyr340/Tyr341 [8]. Src is a non-receptor
protein tyrosine kinase (PTK). The Src family of proteins
contain a Src homology (SH) 2 domain and SH3 domain,
Published: 14 July 2009
BMC Neuroscience 2009, 10:74 doi:10.1186/1471-2202-10-74
Received: 25 March 2009
Accepted: 14 July 2009
This article is available from: http://www.biomedcentral.com/1471-2202/10/74
© 2009 Hu et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Neuroscience 2009, 10:74 http://www.biomedcentral.com/1471-2202/10/74
Page 2 of 9
(page number not for citation purposes)
a catalytic domain, and a C-terminal tail. Src maintains
basal activity in normal cells by an auto-inhibitory mech-
anism, whereby Tyr527 in the C-terminal tail is phospho-
rylated allowing for association with the SH2 domain
preventing catalytic activity. Src activation is initiated
when Tyr527 is dephosphorylated and, subsequently,
autophosphorylated at Tyr-416 [7].
In general, changes in protein phosphorylation require
coordinate regulation of protein kinases and protein
phosphatases. However, to date, the signaling mecha-
nisms leading to dephosphorylation of ERK resulting in
inactivation have not been well defined. Protein phos-
photase 2A (PP2A) has been shown to be an ERK phos-
phatase. Furthermore, it has been suggested that PP2A
dephosphorylates critical residues resulting in ERK inacti-
vation [9-11]. PP2A is a Ser/Thr-specific phosphatase
composed of two regulatory (A and B) and one catalytic
subunit (C) [12]. The catalytic subunit of PP2A (PP2AC)
is regulated by phosphorylation at Tyr307 in the con-
served C-terminal domain of the catalytic subunit result-
ing in inactivation of the enzyme [12,13]. Active Src can
directly phosphorylate PP2A C at Tyr307 [14] and cerebral
ischemia leads to up-regulation of Src activity [15]. How-
ever, whether Src kinase induces ERK activation through
inhibition of PP2A during cerebral ischemia is unclear.
Following ischemia, the activated ERK cascade regulates
gene expression via upregulation of specific transcription
factors [16]. One of the upregulated targets is estrogen
receptor α (ERα), a neuroprotector. It has been reported
that ERα phosphorylation at Ser118 positively regulates
its function and that phospho-ERK phosphorylates this
residue [17-20]. Another neuroprotective protein induced
by ERK activation is cyclic AMP response element-binding
protein (CREB). Additionally, ERK phosphorylates CREB
at Ser133, which is essential for CREB-mediated effects on
transcription [21,22]. Interestingly, this residue has been
shown to be dephosphorylated by PP2A [23,24].
Western blot analyses of p-ERK, p-CREB and p-ERα protein levels and the effect of Src inhibition on them following cerebral  ischemia Figure 1
Western blot analyses of p-ERK, p-CREB and p-ERα protein levels and the effect of Src inhibition on them fol-
lowing cerebral ischemia. SU6656 (SU) and its vehicle (Veh) were administered 20 min before ischemia (I.c.v.) respectively. 
24 h reperfusion after 10 min ischemia was performed. (A) Effect of SU on p-ERK (Thr202/Tyr204) in plasma membrane and 
cytoplasm (M and C) following cerebral ischemia, (B) Effect of SU on p-ERK in nucleus (N) post-ischemia, (C) Role of SU in p-
CREB (Ser118) following post-ischemic reperfusion, (D) Role of SU in p-ERα (Ser133) during reperfusion post-ischemia. Bands 
were scanned and the optical density (O.D.) is presented as fold-increase compared to sham control levels. Data are 
expressed as mean ± S.D. (n = 4/group), #P < 0.05 vs. the respective control group.BMC Neuroscience 2009, 10:74 http://www.biomedcentral.com/1471-2202/10/74
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Therefore, in the present study, we examine the involve-
ment of PP2A in Src-dependent ERK phosphorylation in
the rat hippocampus following ischemia. Through the use
of SU6656 (SU), a Src inhibitor, we show that PP2A activ-
ity is upregulated, which may, in turn, attenuate ERK acti-
vation and its downstream proteins, CREB and ERα, in the
post-ischemic hippocampus. Thus, we propose that Src
induces ERK activation through downregulation of PP2A
activity in cerebral ischemia.
Results
Src inhibitor decreases activity of the ERK/CREB and ERα 
pathways post-ischemia
ERK can be expressed widely and is found in the cell mem-
brane, cytoplasm, and nucleus [16]. Some previous stud-
ies have suggested that the ERK signaling cascade may be
up-regulated in a Src-dependent manner following cere-
bral ischemia [15,25]. Therefore, it was determined if Src
kinase regulates ERK activity at different and specific sub-
cellular sites in response to ischemic stimuli. ERK and p-
ERK were measured by immunoblot in defined subcellu-
lar regions, including the cell membrane, cytoplasm and
nucleus. SU6656 (SU, a selective inhibitor of Src) was
used to inhibit Src activity. Rats underwent 4-VO and
endured 10 min ischemia followed by 24 h reperfusion.
Ischemia leads to phosphorylation of ERK during the 24
h reperfusion post-ischemia in the plasma membrane and
cytoplasm (M and C) and nucleus (N) (Figure. 1A and 1B,
P < 0.05). SU effectively attenuated ERK phosphorylation
after 24 h reperfusion. In addition, no changes were
observed in the total protein levels of ERK. These data
indicate that cerebral ischemia results in an increase in
ERK activity which is independent of subcellular localiza-
tion, but dependent on Src activation in the post-ischemic
hippocampus.
Activated ERK can facilitate the phosphorylation of a vari-
ety of transcription factors phosphorylation involved in
Western blot analyses of p-Src and p-PP2A C levels following post-ischemic reperfusion Figure 2
Western blot analyses of p-Src and p-PP2A C levels following post-ischemic reperfusion. Samples were taken from 
the hippocampi of rats subjected to sham, or 0, 10 min, 1 h, 6 h and 24 h reperfusion after 10 min ischemia. PP2A activity was 
measured using a molybdate dye-based phosphatase assay kit. Sample proteins were identified by special antibodies against p-
Src (Tyr527), Src, PP2A C and p-PP2A C (Tyr307). (A) Temporal curve of PP2A activity following post-ischemic reperfusion. 
(B) Temporal alterations of PP2A C levels during reperfusion post-ischemia. (C) Temporal alterations of p-PP2A C and β-actin 
levels following post-ischemic reperfusion. (D) Temporal alterations of p-Src and Src protein levels after post-ischemic reper-
fusion. O.D. is presented as fold-increase compared to sham control levels. Data are expressed as mean ± S.D. (n = 4/group), 
*P < 0.05 vs. sham control.BMC Neuroscience 2009, 10:74 http://www.biomedcentral.com/1471-2202/10/74
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gene expression [16]. Two proteins regulated by ERK are
CREB and ERα, which are activated by phosphorylation at
the Ser133 residue [22] and at the Ser118 site [20], respec-
tively. In this study, CREB and ERα nuclear activity were
observed in response to cerebral ischemia. Compared
with a sham group, both phospho-CREB and phospho-
ERα are increased in the 24 h reperfusion groups (Figure.
1C and 1D; P < 0.05) and similar to ischemia-induced
ERK activity. To determine whether Src might regulate
CREB and ERα activity following ischemia, SU was
employed. Levels of p-ERα and p-CREB in the 24 h reper-
fusion group showed obvious decrease in animals in
which SU was administered (Figure. 1C and 1D; P < 0.05).
These data suggest that Src kinase is required for activation
of ERK and, subsequently, ERα and CREB post-ischemic
hippocampus.
Src activation is correlated with an increase in PP2A 
phosphorylation and inhibition
In general, ERK, ERα and CREB phosphorylation are
determined by a balance in the activity of upstream
kinases and phosphatases. It has been suggested that the
Ser/Thr-specific phosphatase, PP2A, might negatively reg-
ulate ERK, ERα and CREB activity [26-28]. To examine
whether PP2A is involved in the regulation of the Src/ERK
pathway post-ischemia, it was first assessed whether
ischemia-induced alteration of PP2A activity. All samples
were from rats subjected to various reperfusion times (0,
10 min, 1 h, 6 h and 24 h) after 10 min ischemia. Tissue
extracts of the hippocampi were processed and assayed
using a PP2A activity assay system. The peak of PP2A
activity was observed at approximately 1 h of reperfusion
(approximately 1.5 times higher than the sham group,
Figure. 2A, P < 0.05). Sustained inactivation of PP2A activ-
ity was observed after 6 h and 24 h of reperfusion and was
concomitant with upregulation of the ERK cascade. In
addition, no changes were observed in the total protein of
PP2A C (Figure. 2B, P > 0.05). To confirm inhibition of
PP2A activity, immunoblot were performed to assess
PP2A phosphorylation at the Tyr307 site in the hippoc-
ampus during post-ischemic reperfusion. Hippocampal
tissue extracts were prepared as previously described for
Effects of SU on the Src/PP2A C signaling pathways in response to cerebral ischemia Figure 3
Effects of SU on the Src/PP2A C signaling pathways in response to cerebral ischemia. SU or its Veh was adminis-
tered into the left intracerebral ventricle 20 min prior to occlusion. 24 h post-ischemic reperfusion was performed. Proteins 
were measured using the same antibodies mentioned in Figure 2. (A) Determination of p-Src levels with and without SU during 
24 h reperfusion following 10 min ischemia. (B) Determination of p-PP2A C levels with and without SU following cerebral 
ischemia. (C) Alteration of PP2A C activity following post-ischemic reperfusion. (D) β-actin with and without SU during reper-
fusion post-ischemia. O.D. is presented as fold-increase compared to sham control levels. Data are expressed as mean ± S.D. 
(n = 4/group), *P < 0.05 vs. sham control.BMC Neuroscience 2009, 10:74 http://www.biomedcentral.com/1471-2202/10/74
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Figure. 1. As shown in Figure. 2C, ischemia resulted in
marked dephosphorylation of PP2A at Tyr307 after 1 h
reperfusion, indicating that PP2A activation was induced
by ischemia. However, significant phosphorylation of
PP2A at Tyr307 was observed after 6 h reperfusion (P <
0.05), indicating sustained inactivation of PP2A. Active
Src kinase directly phosphorylates PP2A at Tyr307
[12,29]. Therefore, it was determined whether Src is
required for inactivation of PP2A in cerebral ischemia.
Induction of cerebral ischemia results in dephosphoryla-
tion of Src at Tyr527 increasing its activity at by 6 h reper-
fusion (Figure. 2D, P  < 0.05). Therefore, ischemia-
induced Src activation is accompanied by PP2A inhibi-
tion. No changes were observed in the total protein of Src
and PP2A in each group (Figure 2B–D, P > 0.05). β-actin
protein levels, used as a control, also remained stable in
each group (Figure 2C, P > 0.05).
Inhibition of Src activity results in PP2A increased activity 
in response to cerebral ischemia
The results presented above suggest that activated Src
kinase likely regulates PP2A activity through phosphor-
ylation at Tyr307 following cerebral ischemia. In order to
determine whether Src activation is required for inactiva-
tion of PP2A in cerebral ischemia SU was employed.
Immunoblot was performed to assess p-Src and p-PP2A
levels in the hippocampi of ischemic animals. Rats under-
went 4-VO and endured 10-min ischemia followed by 24
h reperfusion. As shown in Figure 3A, SU produced an
additive increase in Src phosphorylation at Tyr527 site
resulting in a decrease in Src activity, since Tyr527 is an
inhibitive site of Src. In contrast, SU also inhibited PP2A
phosphorylation at Tyr307 after 24 h reperfusion (Figure
3B, P < 0.05). These data indicate that Src activation is
required for PP2A phosphorylation following ischemia.
These same tissue extracts were processed and assayed
Western blot analyses of p-ERK, p-CREB and p-ERα protein levels and the effects of Ct and (or) SU on them in cerebral  ischemia Figure 4
Western blot analyses of p-ERK, p-CREB and p-ERα protein levels and the effects of Ct and (or) SU on them in 
cerebral ischemia. Cantharidin (Ct) and (or) SU were administered at 24 h reperfusion after ischemia. (A) Effect of SU and 
co-administration with Ct and SU on p-ERK in plasma membrane and cytoplasm (M and C) following post-ischemic reper-
fusion, (B) Effect of SU and co-administration with Ct and SU on p – ERK in nucleus (N), (C) Effect of SU and co-administration 
with Ct and SU on p – CREB following post-ischemic reperfusion, (D) Effect of SU and co-administration with Ct on p – ERα 
following post-ischemic reperfusion. The results are expressed as fold changes versus the sham controls. O.D. is presented as 
fold – increase compared to Veh controls. Data are expressed as mean ± S.D. (n = 4/group), #P < 0.05 vs. the respective SU 
administration group.BMC Neuroscience 2009, 10:74 http://www.biomedcentral.com/1471-2202/10/74
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using a PP2A activity assay system. As expected, the PP2A
activity was higher in samples treated with SU compared
with the sham group (Figure 3C, P < 0.05). Furthermore,
the total protein levels of Src, PP2A c and β-actin
remained unchanged in each group (Figure 3A–3D, P >
0.05). These data show that Src activation is required for
PP2A inhibition following cerebral ischemia.
Inhibition of PP2A compensates for inhibition of Src 
allowing for upregulation of ERK/CREB and ERα in the 
presence of SU
Although activated Src kinase decreases PP2A activity after
cerebral ischemia, it is not known whether PP2A is
involved in the Src/ERK cascade following cerebral
ischemia. SU and Cantharidin (Ct), a PP2A inhibitor, was
administered prior to ischemia (i.c.v.), and ERK and p-
ERK protein were examined in the cell membrane, cyto-
plasm and nucleus of post-ischemic hippocampi. As
shown in Figure 4A, samples from animals treated with
both Ct and SU had significantly higher ERK phosphor-
ylation compared with those samples treated with SU
only (P < 0.05). These data demonstrate that ischemia
induces Src activation leading to inhibition of PP2A activ-
ity resulting in ERK activation.
PP2A is also able to dephosphorylate ERK targets, CREB
and ERα. To further assess the role of PP2A in regulation
of signaling cascades during cerebral ischemia, intranu-
clear CREB and ERα immunoblot assays were performed
using specific phosphorylation antibodies. Compared to
samples treated with SU only, both ERα and CREB phos-
phorylations are increased in the Ct and SU co-adminis-
tration samples (P < 0.05; Figure 1B). These data suggest
that Src is required for up-regulation of CREB and ERα
pathway through inhibition of PP2A activity. Total pro-
tein of ERK, CREB and ERα in each group remained
unchanged (Figure 4A–B, P > 0.05).
Discussion
The Raf/ERK pathway couples receptor tyrosine kinase
(RTK) to cell fate decisions, such as growth, proliferation,
migration, differentiation and survival [30]. It is well
known that non-receptor tyrosine kinases, such as Src, can
activate the ERK cascade [6,7]. Our previous studies have
indicated that Src kinase can up-regulate the ERK cascade
through direct phosphorylation of Raf at Tyr340/Tyr341
in response to ischemic stroke [15]. Here, a novel mecha-
nism was identified whereby Src kinase induces the ERK
pathway in a PP2A-dependent manner in rat hippocam-
pus following ischemia (Figure 5).
PP2A is a Ser/Thr-specific phosphatase capable of dephos-
phorylating and inactivating ERK [9,10,29]. Induction of
Src results in inactivation of PP2A resulting in up-regula-
Crosstalk between Raf-dependent, positively regulated signal cascades and a PP2A-dependent negative signaling pathway in cer- ebral ischemia and reperfusion Figure 5
Crosstalk between Raf-dependent, positively regulated signal cascades and a PP2A-dependent negative signal-
ing pathway in cerebral ischemia and reperfusion. In response to ischemia-induced increases in intracellular Ca2+, active 
Src kinase up-regulated ERK cascades through increment of Raf-1 phosphorylation at its active site (Tyr340/341). Meanwhile, 
Src kinase also contributes to ERK activation through increment of PP2A phosphorylation at its inactivation site (Tyr307) in 
cerebral ischemia. These two converse signaling pathways undergo crosstalk through ERK and play important roles in ERK/
CREB and ERα cascades following cerebral ischemia.BMC Neuroscience 2009, 10:74 http://www.biomedcentral.com/1471-2202/10/74
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tion of ERK activity in cerebral ischemia. Several lines of
evidence support the role of PP2A in regulation of the Src/
ERK pathway. First, cerebral ischemia results in sustained
activation of Src kinase after 6 h reperfusion post-
ischemia, accompanied by continuous phosphorylation
of Tyr307 and inhibition of PP2A. Second, SU6656, an
effective Src inhibitor, prevents PP2A phosphorylation
resulting in up-regulation of PP2A activity. Third, can-
tharidin is a specific inhibitor of PP2A, which has little
effect on PP1. Treatment with cantharidin abrogates the
effects of the Src inhibitor, SU6656, allowing for upregu-
lation of ERK activity following ischemia. These results
indicate that Src upregulation of the ERK pathway in
ischemic neurons requires inhibition of PP2A.
Src-induced phosphorylation and inactivation of PP2A
was thought to be closely associated with intracellular cal-
cium signaling [12]. In rat hippocampal neurons, the Src/
ERK cascade is dependent on calcium influx elicited by
upregulation of ion channels like NMDA receptor and IP3
receptor. In addition, inhibition of ion channels can
inhibit Src and ERK activity after cerebral ischemia
[2,4,31]. Our previous studies have also suggested that Src
kinase can up-regulate the Raf/ERK cascade directly in a
calcium-dependent manner following ischemia stroke
[6]. Apparently, Src can activate the ERK cascade via coor-
dinated activation of protein kinases and inactivation of
protein phosphatases in a calcium-dependent manner.
ERK exert their function through up-regulation of nuclear
transcription factors resulting in changes in gene expres-
sion [16]. Our present study indicates that there were no
changes in subcellular localization of total protein levels
of ERK in response to ischemic stimuli. Cerebral ischemia
induced an increase in ERK phosphorylation and activity
in membrane, cytoplasma, and nucleus in hippocampal
neurons. Activated ERK in the nucleus is sufficient to tar-
get its intranuclear substrates like CREB and ERα. As tran-
scription factors, CREB and ERα are localized primarily in
the nucleus of rat hippocampal neurons and their activi-
ties are negatively regulated by PP2A. Therefore, CREB
and ERα share similar mechanisms as downstream mole-
cules of ERK, and are modulated by Src kinase through a
complex signalling network dependent on PP2A inactiva-
tion. CREB and ERα are thought to be protective factors in
the nucleus [20,21]. Upregulation of intranuclear ERK/
CREB and ERα pathway is involved in neuroprotective
gene expression in response to Src signals following cere-
bral ischemia [32].
Conclusion
Activation of Src kinase in neurons during cerebral
ischemia induces a complex signaling network leading to
activation of ERK. In response to ischemia-induced upreg-
ulation of Src kinase, Raf, a positive regulator of the ERK
signaling cascade, is activated. In addition induction of
Src kinase activity also leads to inhibition of PP2A, a neg-
ative regulator of ERK activity. Activation of ERK through
induction of Raf activity and inhibition of PP2A leads to
activation of CREB and ERα, transcription factors, which
is involved in neuronal protection from ischemic stress.
Methods
Transient cerebral ischemia
Adult male Sprague-Dawley rats weighing approximately
250 g (Shanghai Laboratory Animal Center, SLAC, China)
were housed under natural conditions (12-h light/12-h
dark cycle from 07:00 to 18:00 h) at a constant tempera-
ture of 25°C with food and water ad libitum. All animal
surgery was performed in accordance with the Institu-
tional Animal Care and Use Committee and conformed to
international guidelines on the ethical use of animals
(Guide for the Care and Use of Laboratory Animal, 1996).
Before surgery, the animals were deprived of food and
water overnight. Experimental rats were anesthetized with
20% chloral hydrate (300 mg/kg, i.p.) and subjected to
four-vessel occlusion (4VO) according to the method of
Pulsinelli et al., 1982. Briefly, in sterile conditions while
animals were under deep anaesthesia, the bilateral verte-
bral arteries were occluded permanently by electrocauter-
ization and the common carotid arteries were separated
from connective tissue and nerves and marked with surgi-
cal thread. On the following day, ischemia was induced by
bilateral occlusion of the common carotid arteries for 10
min using aneurysm clips. To minimize the experimental
variations, all rats used had to satisfy the following crite-
ria: (1) complete flat electroencephalogram throughout
the duration of carotid occlusion, (2) maintenance of
dilated pupils and an absence of cornea reflex during
ischemia, (3) rigor of the extremities and vertebral col-
umn. Sham operated control rats received the same treat-
ment without carotid artery occlusion. Body temperature
was monitored using a rectal probe and maintained at
approximately 37°C using a heating pad until the animal
had fully recovered from anesthesia.
I.c.v. infusion and administration of inhibitors
Ten microliter microsyringes were used for injections. Pol-
yethylene tubing was used to attach injection cannula to
the microsyringe. A burr hole was drilled in the skull
measured from bregma (0.8 mm posterior, 1.5 mm lateral
and 3.5 mm deep) for administration of chemicals or
vehicle before ischemia. Three microliters of cantharidin
(Ct, 25 μg/μl; Biomol, Plymouth Meeting, PA) and
SU6656 (SU, 5 μM; Calbiochem, La Jolla, CA, USA) (in
DMSO) were administered, either individually or in com-
bination, into the cerebral ventricle (i.c.v.). After the injec-
tion, the injector was retained in place for an additional 5
min in order to reduce any possible backflow of the liquid
along with the injection void. Occlusion occurred 20 min
post-injection.BMC Neuroscience 2009, 10:74 http://www.biomedcentral.com/1471-2202/10/74
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Subcellular fractionation and sample preparation
Rats were euthanized by decapitation at various time
points: 10 min after ischemia or 10 min, 1 h, 6 h, or 24 h
post-reperfusion. The hippocampi were quickly removed
on ice in a cold room [6,33] and the separated brain
regions were homogenized in 1:10 (w/v) ice-cold homog-
enization buffer A (HEPES 50, pH 7.4, KCl 100, Na3VO4
1, NaF 50, and PMSF 1 mM) supplemented with 1%
mammalian protease inhibitor cocktail (Sigma-Aldrich
Co., St. Louis, MO). Cytoplasmic and membrane proteins
were extracted by centrifugation at 800 × g for 20 min at
4°C. Following centrifugation, the supernatant was trans-
ferred into the fresh tubes, which containing the mem-
brane and cytoplasmic proteins (M and C). The resulting
pellet was resuspended in homogenization buffer B
(buffer A, 1 mM DTT, 1% cocktail and 10% NP-40), kept
on ice for 30 min, intensely shaken for 15 min, and then
centrifuged at 14,000 × g for 20 min at 4°C. The superna-
tant contains the nuclear protein (N). All of the superna-
tant was extracted and then stored at -80°C until assayed.
The protein concentrations of the extracts were deter-
mined according to the Bradford assay protocol using
bovine serum albumin (BSA) as a standard (Bradford,
1976).
Western blot analysis
Equivalent amounts of protein lysates were resolved by
10% SDS-PAGE, transferred to nitrocellulose membrane,
incubated in a solution of 3% BSA-Block/TBST for 2 h at
room temperature, and then incubated with primary anti-
body in 1% BSA with shaking at 4°C overnight. Following
three 5–10 min washes in TBST, the membranes were
incubated with secondary antibody conjugated to horse-
radish peroxidase in 1% BSA at room temperature for 2 h.
Following the incubation, membranes were given three
10-min washes with TBST, and then developed using the
Pierce SuperSignal® chemiluminescence kit (Pierce, Rock-
ford, IL). The primary antibodies used were as follows:
mouse anti-phospho-ERK (T202/Y204), rabbit anti-ERK,
rabbit anti-Src, rabbit anti-PP2A C subunit, rabbit anti-
phospho-CREB (Ser133), and rabbit anti-CREB pur-
chased from Cell Signaling Technology (Beverly, MA);
rabbit anti-phospho-ERα (Ser118) and rabbit anti-ERα
purchased from Santa Cruz Biotechnology (Santa Cruz,
CA); rabbit anti-phospho- PP2A (Y307) purchased from
Abcom Biotechnology (Cambridge, UK), rabbit anti-
phospho-Src (Tyr527) purchased from Sigma (St. Louis,
MO);  β-actin purchased from Boster Biotechnology
(WuHan, HB, China). Blots were then washed four times
for 15 min and visualized using enhanced chemilumines-
cence (ECL; Amersham Biosciences, Piscataway, NJ).
PP2A activity assay
PP2A activity was measured with a molybdate dye-based
phosphatase assay kit (Promega, Madison, WI). Assays
were performed according to the manufacturer's protocol.
Briefly, the samples were homogenized in lysis buffer
(Tris-HCl 50, pH 7.4, EDTA 0.1, DTT 1, PMSF 0.1 mM, 1%
Triton X-100 and 1% protease inhibitor cocktail) in ice
water. Samples were filtered through Sephadex G-25 col-
umns to remove free phosphate. The samples were then
added to a reaction premix which contained phosphopep-
tide substrate, 5 × PP2A reaction buffer (250 mM imida-
zole, pH 7.2, 1 mM EGTA, 0.1% β-mercaptoethanol, and
0.5 mg/ml BSA) and storage buffer in 96-well plates. The
reactions were terminated by adding a molybdate dye/
additive mixture and incubating at 37°C for 30 min.
Finally, phosphotase activity in the samples were meas-
ured using a spectrophotometer (Molecular Devices, Sun-
nyvale, CA) at 630 nm wavelength.
Data analysis
In each case, for semi-quantitative analysis, the data from
at least four animals are expressed as the mean ± standard
deviation. Statistical analysis was conducted using an
analysis of variance (ANOVA) followed by the Newman-
Keuls test. Comparisons between two groups were per-
formed using a t-test. P values less than 0.05 were consid-
ered significant.
Abbreviations
ERK: Extracellular signal – regulated kinase; PP2A: Protein
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